MARKET

QLGN

QLGN

Qualigen Therapeutics Inc
NASDAQ
3.590
-0.001
-0.02%
After Hours: 3.590 0 0.00% 16:05 05/09 EDT
OPEN
3.555
PREV CLOSE
3.591
HIGH
3.690
LOW
3.490
VOLUME
2.72K
TURNOVER
--
52 WEEK HIGH
29.44
52 WEEK LOW
2.850
MARKET CAP
2.64M
P/E (TTM)
-0.0640
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at QLGN last week (0428-0502)?
Weekly Report · 5d ago
Qualigen Therapeutics Faces Nasdaq Delisting Threat
TipRanks · 05/01 21:02
Qualigen Therapeutics receives deficiency notice from Nasdaq
Seeking Alpha · 05/01 20:28
Qualigen Therapeutics, Inc. Receives Notification of Deficiency from Nasdaq Related to Delayed Filing of Annual Report on Form 10-K
Barchart · 05/01 15:20
Weekly Report: what happened at QLGN last week (0421-0425)?
Weekly Report · 04/28 12:15
Weekly Report: what happened at QLGN last week (0414-0418)?
Weekly Report · 04/21 12:14
Weekly Report: what happened at QLGN last week (0407-0411)?
Weekly Report · 04/14 12:00
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 04/09 12:07
More
About QLGN
More
Qualigen Therapeutics, Inc. is a clinical-stage therapeutics company. The Company is focused on developing treatments for adult and pediatric cancers. The Company’s business consists of one early-clinical-stage therapeutic program (QN-302) and one preclinical therapeutic program (Pan-RAS). Its lead program, QN-302, is an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor with strong binding affinity to G4s prevalent in cancer cells (such as pancreatic cancer). Its Pan-RAS program, which is at the preclinical stage, consists of a family of rat sarcoma virus (RAS) oncogene protein-protein interaction inhibitor small molecules inhibits or block mutated RAS genes’ proteins from binding to their effector proteins thereby leaving the proteins from the mutated RAS unable to cause further harm. Its QN-302 is in a Phase 1a clinical trial.
Recently
Symbol
Price
%Change

Webull offers Qualigen Therapeutics Inc stock information, including NASDAQ: QLGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QLGN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading QLGN stock methods without spending real money on the virtual paper trading platform.